Literature DB >> 27333213

Diagnosis of upper limb lymphedema: development of an evidence-based approach.

E S Dylke1, G P Schembri2, D L Bailey1, E Bailey2, L C Ward3, K Refshauge1, J Beith4, D Black1, S L Kilbreath1.   

Abstract

BACKGROUND: The diagnosis of secondary upper limb lymphedema (LE) is complicated by the lack of an agreed-upon measurement tool and diagnostic threshold. The aim of this study was to determine which of the many commonly used and normatively determined clinical diagnostic thresholds has the best diagnostic accuracy of secondary upper limb LE, when compared to diagnosis by an appropriate reference standard, lymphoscintigraphy.
MATERIAL AND METHODS: The arms of women treated for breast cancer with and without a previous diagnosis of LE, as well as healthy controls, were assessed using lymphoscintigraphy, bioimpedance spectroscopy (BIS) and perometry. Dermal backflow score determined from lymphoscintigraphy imaging assessment (reference standard) was compared with diagnosis by both commonly used and normatively determined diagnostic thresholds for volume and circumference measurements as well as BIS.
RESULTS: For those with established dermal backflow, all commonly used and normatively determined diagnostic thresholds accurately identified presence of LE compared with lymphoscintigraphy diagnosis. In participants with mild to moderate changes in dermal backflow, only a normatively determined diagnostic threshold, set at two standard deviations above the norm, for arm circumference and full arm BIS were found to have both high sensitivity (81% and 76%, respectively) and specificity (96% and 93%, respectively). For this group, strong, and clinically useful, positive (23 and 10, respectively) and negative likelihood (0.2 and 0.3) ratios were found for both the circumference and bioimpedance diagnostic thresholds.
CONCLUSION: For the first time, evidence-based clinical diagnostic thresholds have been established for secondary LE. With mild LE, normatively determined circumference and BIS thresholds are superior to the commonly used thresholds.

Entities:  

Mesh:

Year:  2016        PMID: 27333213     DOI: 10.1080/0284186X.2016.1191668

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  13 in total

1.  A Prospective Study of L-Dex Values in Breast Cancer Patients Pretreatment and Through 12 Months Postoperatively.

Authors:  Sheila H Ridner; Mary S Dietrich; Kandace Spotanski; Jennifer K Doersam; Michael S Cowher; Bret Taback; Sarah McLaughlin; Nicolas Ajkay; John Boyages; Louise Koelmeyer; Sarah DeSnyder; Chirag Shah; Frank Vicini
Journal:  Lymphat Res Biol       Date:  2018-08-21       Impact factor: 2.589

2.  The Comparative Frequency of Breast Cancer-Related Lymphedema Determined by Bioimpedance Spectroscopy and Circumferential Measurements.

Authors:  Pınar Borman; Ayşegül Yaman; Lütfi Doğan; Ayşe Arıkan Dönmez; Esra Gizem Koyuncu; Ayşegül Balcan; Sercan Aksoy; Cihangir Özaslan; Rabiye Akın; Kaniye Üneş
Journal:  Eur J Breast Health       Date:  2022-04-01

3.  Sensory signs and symptoms in women with self-reported breast cancer-related lymphedema: a case-control study close up.

Authors:  An De Groef; Nele Devoogdt; Ceren Gursen; Niamh Moloney; Victoria Warpy; Jolien Daelemans; Lore Dams; Vincent Haenen; Elien Van der Gucht; An-Kathleen Heroes; Tessa De Vrieze; Elizabeth Dylke
Journal:  J Cancer Surviv       Date:  2021-08-28       Impact factor: 4.062

4.  Utilization of bioimpedance spectroscopy in the prevention of chronic breast cancer-related lymphedema.

Authors:  David I Kaufman; Chirag Shah; Frank A Vicini; Marisa Rizzi
Journal:  Breast Cancer Res Treat       Date:  2017-08-22       Impact factor: 4.872

5.  Changes in volume and incidence of lymphedema during and after treatment with docetaxel, doxorubicin, and cyclophosphamide (TAC) in patients with breast cancer.

Authors:  Janine T Hidding; Carien H G Beurskens; Philip J van der Wees; Wilmy C A M Bos; Maria W G Nijhuis-van der Sanden; Hanneke W M van Laarhoven
Journal:  Support Care Cancer       Date:  2017-11-10       Impact factor: 3.603

6.  Preventing Breast Cancer-Related Lymphedema in High-Risk Patients: The Impact of a Structured Surveillance Protocol Using Bioimpedance Spectroscopy.

Authors:  Pat W Whitworth; Chirag Shah; Frank Vicini; Andrea Cooper
Journal:  Front Oncol       Date:  2018-06-12       Impact factor: 6.244

7.  Correlation of Bioimpedance Spectroscopy with Risk Factors for the Development of Breast Cancer-Related Lymphedema.

Authors:  Frank Vicini; Chirag Shah; Pat Whitworth; Michael Walker; Jing Shi
Journal:  Lymphat Res Biol       Date:  2018-08-22       Impact factor: 2.589

8.  A Comparison of Supine Versus Stand-on Bioimpedance Devices to Assess Breast Cancer-Related Lymphedema.

Authors:  Judy Mastick; Betty J Smoot; Steven M Paul; Kord M Kober; Deborah Hamolsky; Lori K Madden; Yvette P Conley; Niharika Dixit; Marilyn J Hammer; Mei R Fu; Christine Miaskowski
Journal:  Lymphat Res Biol       Date:  2021-02-09       Impact factor: 2.589

9.  Building a Multidisciplinary Comprehensive Academic Lymphedema Program.

Authors:  Mark V Schaverien; Donald P Baumann; Jesse C Selber; Edward I Chang; Matthew M Hanasono; Carrie Chu; Summer E Hanson; Charles E Butler
Journal:  Plast Reconstr Surg Glob Open       Date:  2020-03-20

10.  Reference values of bioelectrical impedance analysis for detecting breast cancer-related lymphedema.

Authors:  Minji Jung; Jae Yong Jeon; Gi Jeong Yun; Seoyon Yang; Sara Kwon; Yu Jin Seo
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.